Globus Medical (NYSE:GMED) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
How the Narrative Around Globus Medical Is Evolving After Recent Analyst and Market Updates [Yahoo! Finance]
A Look at Globus Medical (GMED) Valuation Following Its Recent 31% Share Price Rebound [Yahoo! Finance]
10 Years Later: 5 Lesser-Known Rule Breakers [Yahoo! Finance]
Globus Medical (NYSE:GMED) had its "buy" rating reaffirmed by analysts at Truist Financial Corporation. They now have a $105.00 price target on the stock, up previously from $93.00.